Mesoblast Limited
MESO · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $17 | $6 | $8 | $10 |
| % Growth | 191.4% | -21.3% | -26.5% | – |
| Cost of Goods Sold | $5 | $41 | $55 | $64 |
| Gross Profit | $12 | -$35 | -$47 | -$53 |
| % Margin | 70.2% | -595.9% | -632.2% | -522.6% |
| R&D Expenses | $35 | $25 | $27 | $33 |
| G&A Expenses | $23 | $24 | $25 | $27 |
| SG&A Expenses | $39 | $24 | $53 | $58 |
| Sales & Mktg Exp. | $16 | $0 | $28 | $31 |
| Other Operating Expenses | $0 | $0 | $0 | $31 |
| Operating Expenses | $75 | $49 | $77 | $91 |
| Operating Income | -$62 | -$84 | -$69 | -$81 |
| % Margin | -363.1% | -1,425.7% | -923.7% | -789.1% |
| Other Income/Exp. Net | -$39 | -$4 | -$13 | -$10 |
| Pre-Tax Income | -$102 | -$88 | -$82 | -$92 |
| Tax Expense | $0 | -$0 | -$0 | -$0 |
| Net Income | -$102 | -$88 | -$82 | -$91 |
| % Margin | -593.9% | -1,490.3% | -1,091.7% | -894.6% |
| EPS | -0.84 | -0.89 | -0.98 | -1.3 |
| % Growth | 5.6% | 9.2% | 24.6% | – |
| EPS Diluted | -0.84 | -0.89 | -0.98 | -1.3 |
| Weighted Avg Shares Out | 121 | 99 | 84 | 68 |
| Weighted Avg Shares Out Dil | 121 | 99 | 84 | 68 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $2 | $1 | $0 |
| Interest Expense | $23 | $21 | $19 | $17 |
| Depreciation & Amortization | $6 | $2 | $4 | $4 |
| EBITDA | -$74 | -$56 | -$59 | -$77 |
| % Margin | -428.3% | -950.1% | -780.6% | -749.9% |